BioCentury
ARTICLE | Company News

Telix, Atlab deal

February 10, 2017 8:13 PM UTC

Telix and single-asset company Atlab partnered to develop radiolabeled variants of Atlab's huJ591 to treat metastatic prostate cancer. Telix also gained an exclusive option to acquire Atlab and has on...

BCIQ Company Profiles

Telix Pharmaceuticals Ltd.